Search

Author/Creator Harrison, Michael R

1. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Issue 4 (April 2019)

Authors:
Martínez Chanzá, Nieves; Xie, Wanling; Asim Bilen, Mehmet; Dzimitrowicz, Hannah; Burkart, Jarred; Geynisman, Daniel M; Balakrishnan, Archana; Bowman, I Alex; Jain, Rohit; Stadler, Walter; Zakharia, Yousef; Narayan, Vivek; Beuselinck, Benoit; McKay, Rana R; Tripathi, Abhishek; Pachynski, Russell; ...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 4(2019)
Page Start:
581
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Issue 6 (June 2021)

Authors:
Yu, Evan Y; Petrylak, Daniel P; O'Donnell, Peter H; Lee, Jae-Lyun; van der Heijden, Michiel S; Loriot, Yohann; Stein, Mark N; Necchi, Andrea; Kojima, Takahiro; Harrison, Michael R; Hoon Park, Se; Quinn, David I; Heath, Elisabeth I; Rosenberg, Jonathan E; Steinberg, Joyce; Liang, Shang-Ying; Trowb...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 6(2021)
Page Start:
872
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. Issue 3 (2nd March 2021)

Authors:
Brown, Landon C; Tucker, Matthew D; Sedhom, Ramy; Schwartz, Eric B; Zhu, Jason; Kao, Chester; Labriola, Matthew K; Gupta, Rajan T; Marin, Daniele; Wu, Yuan; Gupta, Santosh; Zhang, Tian; Harrison, Michael R; George, Daniel J; Alva, Ajjai; Antonarakis, Emmanuel S; Armstrong, Andrew J
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 9:Issue 3(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. (4th November 2015)

Authors:
Sznol, Mario; Fishman, Mayer; Escudier, Bernard; McDermott, David F; Kluger, Harriet; Stadler, Walter M; Perez-Gracia, Jose; McNeel, Douglas G; Curti, Brendan D; Harrison, Michael R; Plimack, Elizabeth R; Appleman, Leonard; Fong, Lawrence; Drake, Charles G; Young, Tina C; Chasalow, Scott D; Ross-...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Issue 10 (October 2019)

Authors:
Motzer, Robert J; Rini, Brian I; McDermott, David F; Arén Frontera, Osvaldo; Hammers, Hans J; Carducci, Michael A; Salman, Pamela; Escudier, Bernard; Beuselinck, Benoit; Amin, Asim; Porta, Camillo; George, Saby; Neiman, Victoria; Bracarda, Sergio; Tykodi, Scott S; Barthélémy, Philippe; Leibowitz-...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 10(2019)
Page Start:
1370
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. Issue 2 (24th February 2022)

Authors:
Tykodi, Scott S; Gordan, Lucio N; Alter, Robert S; Arrowsmith, Edward; Harrison, Michael R; Percent, Ivor; Singal, Rakesh; Van Veldhuizen, Peter; George, Daniel J; Hutson, Thomas; Zhang, Joshua; Zoco, Jesus; Johansen, Jennifer L; Rezazadeh Kalebasty, Arash
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 2(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗